Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements | Journal of Clinical Oncology | 2012 | 582 |
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study | Leukemia | 2012 | 580 |
Clonal competition with alternating dominance in multiple myeloma | Blood | 2012 | 473 |
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant | Blood | 2012 | 362 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma | Blood | 2012 | 335 |
Concurrent validity of single-item measures of emotional exhaustion and depersonalization in burnout assessment | Journal of General Internal Medicine | 2012 | 274 |
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs | Journal of Clinical Oncology | 2012 | 252 |
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma | Journal of Clinical Investigation | 2012 | 192 |
Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution | Clinical Journal of the American Society of Nephrology: CJASN | 2012 | 191 |
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics | Blood | 2012 | 181 |
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment | Blood | 2012 | 172 |
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS) | American Heart Journal | 2012 | 167 |
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value | Blood | 2012 | 164 |
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas | Blood | 2012 | 164 |
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study | Neuro-Oncology | 2012 | 160 |
Methodology for isolation, identification and characterization of microvesicles in peripheral blood | Journal of Immunological Methods | 2012 | 154 |
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma | Haematologica | 2012 | 151 |
IMWG consensus on maintenance therapy in multiple myeloma | Blood | 2012 | 150 |
VEGF inhibition, hypertension, and renal toxicity | Current Oncology Reports | 2012 | 148 |
The high cost of cancer drugs and what we can do about it | Mayo Clinic Proceedings | 2012 | 143 |
The clinical spectrum of Castleman's disease | American Journal of Hematology | 2012 | 141 |
One thousand patients with primary myelofibrosis: the mayo clinic experience | Mayo Clinic Proceedings | 2012 | 137 |
Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer | International Journal of Radiation Oncology Biology Physics | 2012 | 132 |
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths | Blood | 2012 | 129 |
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F | Leukemia | 2012 | 129 |